SG11201708151TA - Method of monomerisation of recombinant antibody molecules - Google Patents
Method of monomerisation of recombinant antibody moleculesInfo
- Publication number
- SG11201708151TA SG11201708151TA SG11201708151TA SG11201708151TA SG11201708151TA SG 11201708151T A SG11201708151T A SG 11201708151TA SG 11201708151T A SG11201708151T A SG 11201708151TA SG 11201708151T A SG11201708151T A SG 11201708151TA SG 11201708151T A SG11201708151T A SG 11201708151TA
- Authority
- SG
- Singapore
- Prior art keywords
- monomerisation
- antibody molecules
- recombinant antibody
- recombinant
- molecules
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
- C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
- C07K1/1133—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure by redox-reactions involving cystein/cystin side chains
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
- C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
- C07K1/1136—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure by reversible modification of the secondary, tertiary or quarternary structure, e.g. using denaturating or stabilising agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/10—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C323/11—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
- C07C323/12—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
- C07C323/24—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
- C07C323/25—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/12—Cyclic peptides with only normal peptide bonds in the ring
- C07K5/123—Tripeptides
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Analytical Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Crystallography & Structural Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1506870.3A GB201506870D0 (en) | 2015-04-22 | 2015-04-22 | Method |
| PCT/EP2016/059051 WO2016170138A1 (en) | 2015-04-22 | 2016-04-22 | Method of monomerisation of recombinant antibody molecules |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201708151TA true SG11201708151TA (en) | 2017-11-29 |
Family
ID=53299019
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201708151TA SG11201708151TA (en) | 2015-04-22 | 2016-04-22 | Method of monomerisation of recombinant antibody molecules |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US10828366B2 (enExample) |
| EP (1) | EP3286204B1 (enExample) |
| JP (1) | JP6898251B2 (enExample) |
| KR (1) | KR20170138552A (enExample) |
| CN (1) | CN108064230B (enExample) |
| AU (1) | AU2016251620A1 (enExample) |
| BR (1) | BR112017021812A2 (enExample) |
| CA (1) | CA2981644C (enExample) |
| CL (1) | CL2017002676A1 (enExample) |
| CO (1) | CO2017010385A2 (enExample) |
| EA (1) | EA201792329A1 (enExample) |
| ES (1) | ES2846732T3 (enExample) |
| GB (1) | GB201506870D0 (enExample) |
| IL (1) | IL254765A0 (enExample) |
| MX (1) | MX2017013376A (enExample) |
| SG (1) | SG11201708151TA (enExample) |
| WO (1) | WO2016170138A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201223276D0 (en) * | 2012-12-21 | 2013-02-06 | Ucb Pharma Sa | Antibodies and methods of producing same |
| FI3237433T3 (fi) | 2014-12-22 | 2025-10-14 | UCB Biopharma SRL | Menetelmä proteiinin valmistamiseksi |
| GB201506868D0 (en) | 2015-04-22 | 2015-06-03 | Ucb Biopharma Sprl | Method for protein purification |
| GB201506870D0 (en) | 2015-04-22 | 2015-06-03 | Ucb Biopharma Sprl | Method |
| GB201506869D0 (en) | 2015-04-22 | 2015-06-03 | Ucb Biopharma Sprl | Method |
| AR117650A1 (es) * | 2018-10-11 | 2021-08-18 | Amgen Inc | Procesamiento posterior de constructos de anticuerpos biespecíficos |
| PH12021551479A1 (en) * | 2018-12-21 | 2022-07-18 | Novartis Ag | Antibodies to pmel17 and conjugates thereof |
| KR20230117588A (ko) * | 2020-12-07 | 2023-08-08 | 유씨비 바이오파마 에스알엘 | 다중특이적 항체 및 항체 조합 |
Family Cites Families (83)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4741900A (en) | 1982-11-16 | 1988-05-03 | Cytogen Corporation | Antibody-metal ion complexes |
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| DK336987D0 (da) | 1987-07-01 | 1987-07-01 | Novo Industri As | Immobiliseringsmetode |
| US5453363A (en) | 1985-10-23 | 1995-09-26 | Boehringer Mannheim Gmbh | Process for the activation of t-PA or Ing after genetic expression in prokaryotes |
| GB8719042D0 (en) | 1987-08-12 | 1987-09-16 | Parker D | Conjugate compounds |
| GB8720833D0 (en) | 1987-09-04 | 1987-10-14 | Celltech Ltd | Recombinant dna product |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| EP0768377A1 (en) | 1988-09-02 | 1997-04-16 | Protein Engineering Corporation | Generation and selection of recombinant varied binding proteins |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| GB8907617D0 (en) | 1989-04-05 | 1989-05-17 | Celltech Ltd | Drug delivery system |
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| AU7247191A (en) | 1990-01-11 | 1991-08-05 | Molecular Affinities Corporation | Production of antibodies using gene libraries |
| US5780225A (en) | 1990-01-12 | 1998-07-14 | Stratagene | Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules |
| ES2284161T3 (es) | 1990-01-12 | 2007-11-01 | Amgen Fremont Inc. | Generacion de anticuerpos xenogenicos. |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| CA2090126C (en) | 1990-08-02 | 2002-10-22 | John W. Schrader | Methods for the production of proteins with a desired function |
| AU8507191A (en) | 1990-08-29 | 1992-03-30 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5698426A (en) | 1990-09-28 | 1997-12-16 | Ixsys, Incorporated | Surface expression libraries of heteromeric receptors |
| ES2113940T3 (es) | 1990-12-03 | 1998-05-16 | Genentech Inc | Metodo de enriquecimiento para variantes de proteinas con propiedades de union alteradas. |
| AU662148B2 (en) | 1991-04-10 | 1995-08-24 | Scripps Research Institute, The | Heterodimeric receptor libraries using phagemids |
| GB9112536D0 (en) | 1991-06-11 | 1991-07-31 | Celltech Ltd | Chemical compounds |
| GB9120467D0 (en) | 1991-09-26 | 1991-11-06 | Celltech Ltd | Anti-hmfg antibodies and process for their production |
| PT1696031E (pt) | 1991-12-02 | 2010-06-25 | Medical Res Council | Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos |
| WO1993016185A2 (en) * | 1992-02-06 | 1993-08-19 | Creative Biomolecules, Inc. | Biosynthetic binding protein for cancer marker |
| US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| JPH09506262A (ja) | 1993-12-08 | 1997-06-24 | ジェンザイム・コーポレイション | 特異的抗体の製造方法 |
| PT744958E (pt) | 1994-01-31 | 2003-11-28 | Univ Boston | Bancos de anticorpos policlonais |
| FR2716640B1 (fr) | 1994-02-28 | 1996-05-03 | Procedes Machines Speciales | Dispositif de centrage et de blocage d'une pièce en vue de son rodage à l'aide d'un rodoir à expansion. |
| US5516637A (en) | 1994-06-10 | 1996-05-14 | Dade International Inc. | Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage |
| JP2978435B2 (ja) | 1996-01-24 | 1999-11-15 | チッソ株式会社 | アクリロキシプロピルシランの製造方法 |
| US5980898A (en) | 1996-11-14 | 1999-11-09 | The United States Of America As Represented By The U.S. Army Medical Research & Material Command | Adjuvant for transcutaneous immunization |
| GB9625640D0 (en) | 1996-12-10 | 1997-01-29 | Celltech Therapeutics Ltd | Biological products |
| CA2362550C (en) * | 1999-02-22 | 2010-05-11 | Georgetown University | Antibody fragment-targeted immunoliposomes for systemic gene delivery |
| US6908963B2 (en) | 2001-10-09 | 2005-06-21 | Nektar Therapeutics Al, Corporation | Thioester polymer derivatives and method of modifying the N-terminus of a polypeptide therewith |
| SG187991A1 (en) | 2002-05-02 | 2013-03-28 | Wyeth Corp | Calicheamicin derivative-carrier conjugates |
| WO2003097669A2 (en) * | 2002-05-17 | 2003-11-27 | Københavns Universitet | Method for purifying denatured proteins having a desired disulfide bond configuration |
| US7993864B2 (en) | 2002-12-03 | 2011-08-09 | Ucb Pharma S.A. | Assay for identifying antibody producing cells |
| GB0312481D0 (en) | 2003-05-30 | 2003-07-09 | Celltech R&D Ltd | Antibodies |
| GB0315457D0 (en) | 2003-07-01 | 2003-08-06 | Celltech R&D Ltd | Biological products |
| GB0315450D0 (en) * | 2003-07-01 | 2003-08-06 | Celltech R&D Ltd | Biological products |
| HUE026278T2 (en) | 2003-07-01 | 2016-05-30 | Ucb Biopharma Sprl | Modified Fab antibody fragments |
| GB0412181D0 (en) | 2004-06-01 | 2004-06-30 | Celltech R&D Ltd | Biological products |
| MXPA06014065A (es) | 2004-06-01 | 2007-01-31 | Genentech Inc | Conjugados de droga-anticuerpo y metodos. |
| US20060051347A1 (en) | 2004-09-09 | 2006-03-09 | Winter Charles M | Process for concentration of antibodies and therapeutic products thereof |
| SG156672A1 (en) | 2004-10-22 | 2009-11-26 | Amgen Inc | Methods for refolding of recombinant antibodies |
| AU2006272714A1 (en) | 2005-07-25 | 2007-02-01 | Trubion Pharmaceuticals, Inc. | Compositions and methods for protein deaggregation |
| WO2007038619A2 (en) | 2005-09-27 | 2007-04-05 | Amunix, Inc. | Proteinaceous pharmaceuticals and uses thereof |
| GB0619291D0 (en) | 2006-09-29 | 2006-11-08 | Ucb Sa | Altered antibodies |
| US8629246B2 (en) | 2007-09-26 | 2014-01-14 | Ucb Pharma S.A. | Dual specificity antibody fusions |
| WO2010019493A1 (en) | 2008-08-14 | 2010-02-18 | Merck Sharp & Dohme Corp. | Methods for purifying antibodies using protein a affinity chromatography |
| WO2010035012A1 (en) | 2008-09-26 | 2010-04-01 | Ucb Pharma S.A. | Biological products |
| EP2342318A1 (en) * | 2008-09-26 | 2011-07-13 | Schering Corporation | High titer antibody production |
| SI3660032T1 (sl) | 2009-06-25 | 2026-02-27 | Amgen Inc. | Postopki zajemanja in čiščenja beljakovin, izraženih v nesesalskem sistemu |
| ES2667258T3 (es) | 2009-09-10 | 2018-05-10 | Ucb Biopharma Sprl | Anticuerpos multivalentes |
| GB201005063D0 (en) | 2010-03-25 | 2010-05-12 | Ucb Pharma Sa | Biological products |
| GB0920127D0 (en) | 2009-11-17 | 2009-12-30 | Ucb Pharma Sa | Antibodies |
| GB201000467D0 (en) | 2010-01-12 | 2010-02-24 | Ucb Pharma Sa | Antibodies |
| WO2011113601A1 (en) * | 2010-03-17 | 2011-09-22 | Biogenerix Ag | Method for obtaining biologically active recombinant human g-csf |
| EP2550297B1 (en) | 2010-03-25 | 2019-01-23 | UCB Biopharma SPRL | Disulfide stabilized dvd-lg molecules |
| GB201005064D0 (en) | 2010-03-25 | 2010-05-12 | Ucb Pharma Sa | Biological products |
| JP5903101B2 (ja) * | 2010-09-20 | 2016-04-13 | バイオ−ラッド ラボラトリーズ インコーポレーティッド | クロマトグラフィーにおける生成物と複合体形成した夾雑物の分離方法 |
| US8759617B2 (en) * | 2010-09-21 | 2014-06-24 | National Institute Of Agrobiological Sciences | Method for extraction and purification of recombinant proteins from transgenic plants |
| JP2014527072A (ja) * | 2011-09-09 | 2014-10-09 | バイオメド リアルティー， エル．ピー． | ウイルスタンパク質の集合を制御するための方法および組成物 |
| US9803004B2 (en) | 2011-11-11 | 2017-10-31 | Ucb Biopharma Sprl | Albumin binding antibodies and binding fragments thereof |
| UA112203C2 (uk) | 2011-11-11 | 2016-08-10 | Юсб Фарма С.А. | Злитий білок біоспецифічного антитіла, який зв'язується з ox40 людини та сироватковим альбуміном людини |
| EP2831089A1 (en) | 2012-03-30 | 2015-02-04 | Krishnan, Archana Rajesh | Process for renaturation of polypeptides |
| GB201208370D0 (en) | 2012-05-14 | 2012-06-27 | Ucb Pharma Sa | Antibodies |
| ES2831374T3 (es) | 2012-11-21 | 2021-06-08 | Janssen Biotech Inc | Anticuerpos de EGFR/c-Met biespecíficos |
| WO2015134785A1 (en) | 2014-03-07 | 2015-09-11 | Bionano Genomics, Inc. | Processing of polynucleotides |
| GB201411320D0 (en) | 2014-06-25 | 2014-08-06 | Ucb Biopharma Sprl | Antibody construct |
| GB201506869D0 (en) | 2015-04-22 | 2015-06-03 | Ucb Biopharma Sprl | Method |
| GB201506870D0 (en) * | 2015-04-22 | 2015-06-03 | Ucb Biopharma Sprl | Method |
| GB201506868D0 (en) | 2015-04-22 | 2015-06-03 | Ucb Biopharma Sprl | Method for protein purification |
| EP3485280A1 (en) | 2016-08-12 | 2019-05-22 | Lonza Ltd | Proteomic analysis of host cell proteins |
-
2015
- 2015-04-22 GB GBGB1506870.3A patent/GB201506870D0/en not_active Ceased
-
2016
- 2016-04-22 US US15/566,307 patent/US10828366B2/en active Active
- 2016-04-22 EA EA201792329A patent/EA201792329A1/ru unknown
- 2016-04-22 CA CA2981644A patent/CA2981644C/en active Active
- 2016-04-22 SG SG11201708151TA patent/SG11201708151TA/en unknown
- 2016-04-22 ES ES16719824T patent/ES2846732T3/es active Active
- 2016-04-22 BR BR112017021812A patent/BR112017021812A2/pt not_active Application Discontinuation
- 2016-04-22 JP JP2017555223A patent/JP6898251B2/ja not_active Expired - Fee Related
- 2016-04-22 WO PCT/EP2016/059051 patent/WO2016170138A1/en not_active Ceased
- 2016-04-22 MX MX2017013376A patent/MX2017013376A/es unknown
- 2016-04-22 EP EP16719824.1A patent/EP3286204B1/en active Active
- 2016-04-22 CN CN201680022972.8A patent/CN108064230B/zh not_active Expired - Fee Related
- 2016-04-22 KR KR1020177033853A patent/KR20170138552A/ko not_active Abandoned
- 2016-04-22 AU AU2016251620A patent/AU2016251620A1/en not_active Abandoned
-
2017
- 2017-09-28 IL IL254765A patent/IL254765A0/en unknown
- 2017-10-11 CO CONC2017/0010385A patent/CO2017010385A2/es unknown
- 2017-10-20 CL CL2017002676A patent/CL2017002676A1/es unknown
-
2020
- 2020-10-23 US US17/078,127 patent/US11786593B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP6898251B2 (ja) | 2021-07-07 |
| EP3286204B1 (en) | 2020-11-18 |
| US20210069328A1 (en) | 2021-03-11 |
| CN108064230B (zh) | 2021-04-06 |
| CA2981644A1 (en) | 2016-10-27 |
| BR112017021812A2 (pt) | 2018-07-10 |
| CO2017010385A2 (es) | 2018-03-20 |
| EA201792329A1 (ru) | 2018-02-28 |
| US10828366B2 (en) | 2020-11-10 |
| MX2017013376A (es) | 2017-12-07 |
| IL254765A0 (en) | 2017-12-31 |
| CL2017002676A1 (es) | 2018-03-23 |
| ES2846732T3 (es) | 2021-07-29 |
| KR20170138552A (ko) | 2017-12-15 |
| CA2981644C (en) | 2023-07-04 |
| AU2016251620A1 (en) | 2017-10-26 |
| US20180117153A1 (en) | 2018-05-03 |
| JP2018515449A (ja) | 2018-06-14 |
| WO2016170138A1 (en) | 2016-10-27 |
| EP3286204A1 (en) | 2018-02-28 |
| CN108064230A (zh) | 2018-05-22 |
| US11786593B2 (en) | 2023-10-17 |
| GB201506870D0 (en) | 2015-06-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL285366A (en) | Multi-specific antigen-binding proteins | |
| ZA201907054B (en) | Anti-tau antibodies and methods of use | |
| IL257565A (en) | Improved variants of anti-vegf antibodies | |
| IL249955A0 (en) | A method for the computational design of proteins | |
| GB201601075D0 (en) | Antibodies molecules | |
| GB201518792D0 (en) | Production of proteins | |
| IL254765A0 (en) | A method for the monomerization of recombinant antibody molecules | |
| EP3297661A4 (en) | Method of improving characteristics of proteins | |
| HUP1500363A2 (en) | Method for increasing the galactose content of recombinant proteins | |
| GB201522391D0 (en) | Antibody molecules | |
| PL3313877T3 (pl) | Humanizowane przeciwciała przeciwko białku tau(pS422) i sposoby stosowania | |
| SG11201803356SA (en) | Anti-htra1 antibodies and methods of use thereof | |
| GB201503812D0 (en) | Antibody molecules and uses thereof | |
| IL248697A0 (en) | Methods for purifying antibodies | |
| IL255094A0 (en) | A method for increasing the percentage of multimeric strains for a monomeric dsfv-fab antibody | |
| LT3337820T (lt) | Patobulintas antikūnų fragmentų refoldingo būdas | |
| PL3189336T3 (pl) | Sposób określania ryzyka stanu przedrzucawkowego | |
| GB201604627D0 (en) | Improved method of FT-IMS | |
| IL258981A (en) | Methods for the production of proteins | |
| SG11201800894SA (en) | Method for parallel quantification of protein variant | |
| IL252712A0 (en) | Method for protein production | |
| GB201518675D0 (en) | Detection of structural forms of proteins | |
| IL248694B (en) | Nanoencapsulation of antigen binding molecules | |
| IL256707B (en) | A method for the production of recombinant proteins | |
| IL256706B (en) | A method for making recombinant proteins |